Myeloma
Research on myeloma discussed by scientists at University of Athens
Published in Cancer Weekly, February 9th, 2010
In this recent study, researchers in Athens, Greece conducted a study "To assess bortezomib plus melphalan and prednisone (VMP) and melphalan and prednisone (MP) in previously untreated patients with multiple myeloma (MM) with renal impairment enrolled on the phase III VISTA study, and to evaluate renal impairment reversibility. Patients received nine 6-week cycles of VMP (bortezomib 1.3 mg/m(2), melphalan 9 mg/m(2), prednisone 60 mg/m(2)) or MP."
"with serum creatinine higher than 2 mg/dL were excluded. In the VMP/MP arms, 6%/4%, 27%/30%, and 67%/66% of patients had baseline glomerular filtration rate (GFR) of <= 30, 31 to 50, and higher than 50 mL/min,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2010-02-09)
More Articles from Cancer Weekly
- American College of Radiology / American Roentgen Ray Society
Virtual colonoscopy an effective colorectal cancer screening exam in Medicare age patients - Cytori Therapeutics
Cell-enriched fat grafts improve long term graft retention in preclinical study - Dana-Farber Cancer Institute
Genes found linked to breast cancer drug resistance could guide future treatment choices - Institute for Quality and Efficiency in Health Care
Women with breast cancer may benefit from autologous stem cell transplantation - JAMA and Archives Journals
Physical activity associated with healthier aging - Journal of the National Cancer Institute
News brief: Childhood survivors of CNS cancers and leukemia have lowered educational attainment - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
